E170检测血清TPSA、FPSA及FPSA/TPSA在前列腺疾病诊断中的应用价值

Application of serum TPSA,FPSA detections and FPSA/TPSA evaluation for diagnosis and therapy of prostatic diseases with E170 technique

目的:探讨E170检测血清TPSA、FPSA及FPSA/TPSA比值在前列腺疾病诊断中的应用价值。方法:应用E170电化学发光免疫分析(ECLIA)法检测正常对照组(40例)、前列腺炎组(78例)、前列腺增生组(64例)及前列腺癌组(35例)血清TPSA、FPSA含量及FPSA/TPSA。结果:前列腺癌组TPSA、FPSA、FPSA/TPSA与其他3组比较差异均有显著性(P<0.05),前列腺增生组TPSA、FPSA、FPSA/TPSA与另两组(正常组和前列腺炎组)比较差异也有显著性(P<0.05),而正常组与前列腺炎组之间比较差异无显著性(P>0.05);在TPSA不同水平阶段,前列腺增生与前列腺癌所占比率不同(P<0.05);在不同年龄阶段,前列腺癌的所占比率不同(P<0.05)。结论:应用ECLIA检测TPSA、FPSA含量及FPSA/TPSA是提高前列腺疾病诊断与鉴别诊断更为有效的方法,尤其对前列腺癌诊断更有意义。

Objective ：To investigate the application of TPSA, FPSA coneent rations and FPSA/TPSA value for diagnosis and therapy of prostatic diseases detected with E170 electrochemiluminescent immunoassay （ECLIA） technique. Methods：40 cases of normal individuals were used as control group, 78 patients with prostatitisas prostatitis group, 64 patients with prostatic hyperplasia as BPH group and 35 patients with prostate cancer asprostate cancer group. TPSA, FPSA concent rations and FPSA/TPSA value were detected with ECLIA technique. Results ：In prostate cancer group, the TPSA, FPSA and TPSA/FPSA coneent rations were significantly higher than those in other 3 groups （P〈0. 05）. However, there was no significant difference between the control group and the prostatitisas prostatitis group （P〉0. 05）. The percentage of patients shared in different level of TPSA had significant difference between BPH group and PC group （P〈0. 05）. The percentage of PC in different age had significant difference （P〈0. 05）. Conclusion： ECLIA technique is an effective method to improve the diagnosis and differential diagnosis of prostaticdiseases, especially for prostate cancer.